237 related articles for article (PubMed ID: 37342346)
1. Telitacicept for autoimmune nephropathy.
Cai J; Gao D; Liu D; Liu Z
Front Immunol; 2023; 14():1169084. PubMed ID: 37342346
[TBL] [Abstract][Full Text] [Related]
2. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
3. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
Samy E; Wax S; Huard B; Hess H; Schneider P
Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
[TBL] [Abstract][Full Text] [Related]
4. Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.
Evans LS; Lewis KE; DeMonte D; Bhandari JG; Garrett LB; Kuijper JL; Ardourel D; Wolfson MF; Debrot S; Mudri S; Kleist K; Griffin LL; Hebb L; Sanderson RJ; Wang N; Seaberg M; Chunyk AG; Yang J; Hong Y; Maria Z; Messenheimer DJ; Holland PM; Peng SL; Rixon MW; Dillon SR
Arthritis Rheumatol; 2023 Jul; 75(7):1187-1202. PubMed ID: 36705554
[TBL] [Abstract][Full Text] [Related]
5. Intrarenal production of B-cell survival factors in human lupus nephritis.
Neusser MA; Lindenmeyer MT; Edenhofer I; Gaiser S; Kretzler M; Regele H; Segerer S; Cohen CD
Mod Pathol; 2011 Jan; 24(1):98-107. PubMed ID: 20890272
[TBL] [Abstract][Full Text] [Related]
6. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
Fan Y; Gao D; Zhang Z
Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
[TBL] [Abstract][Full Text] [Related]
7. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
Arkatkar T; Jacobs HM; Du SW; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
Kidney Int; 2018 Oct; 94(4):728-740. PubMed ID: 29907458
[TBL] [Abstract][Full Text] [Related]
8. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
Ma X; Fu X; Cui B; Lin H
Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
[TBL] [Abstract][Full Text] [Related]
9. Telitacicept: First Approval.
Dhillon S
Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
[TBL] [Abstract][Full Text] [Related]
10. Role of telitacicept in the treatment of IgA nephropathy.
Wu L; Du X; Lu X
Eur J Med Res; 2023 Sep; 28(1):369. PubMed ID: 37737205
[TBL] [Abstract][Full Text] [Related]
11. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
[TBL] [Abstract][Full Text] [Related]
12. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
[TBL] [Abstract][Full Text] [Related]
14. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
15. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
[TBL] [Abstract][Full Text] [Related]
16. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis.
Phatak S; Chaurasia S; Mishra SK; Gupta R; Agrawal V; Aggarwal A; Misra R
Clin Exp Immunol; 2017 Mar; 187(3):376-382. PubMed ID: 27804111
[TBL] [Abstract][Full Text] [Related]
17. Integrated B Cell, Toll-like, and BAFF Receptor Signals Promote Autoantibody Production by Transitional B Cells.
Du SW; Jacobs HM; Arkatkar T; Rawlings DJ; Jackson SW
J Immunol; 2018 Dec; 201(11):3258-3268. PubMed ID: 30373855
[TBL] [Abstract][Full Text] [Related]
18. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus.
Vincent FB; Northcott M; Hoi A; Mackay F; Morand EF
Lupus; 2013 Aug; 22(9):873-84. PubMed ID: 23846230
[TBL] [Abstract][Full Text] [Related]
19. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.
Schwarting A; Relle M; Meineck M; Föhr B; Triantafyllias K; Weinmann A; Roth W; Weinmann-Menke J
Lupus; 2018 Feb; 27(2):243-256. PubMed ID: 28659046
[TBL] [Abstract][Full Text] [Related]
20. Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus.
Ortiz-Aljaro P; Montes-Cano MA; García-Lozano JR; Aquino V; Carmona R; Perez-Florido J; García-Hernández FJ; Dopazo J; González-Escribano MF
Sci Rep; 2022 Jul; 12(1):11219. PubMed ID: 35780200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
